Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Castle Biosciences reported after the close of the market on Wednesday that its third quarter revenues rose 58 percent year over year, driven by record diagnostic test volume for the firm.

On October 27, Mindray (300760) released its third quarterly report. The report showed that in the first three quarters of 2022, Mindray achieved revenue of CNY 23.3 billion, an increase of 20.1% year-on-year, and recorded net profit of CNY 8.1 billion, an increase of 21.6% year-on-year.

Hologic reported after the close of the market on Monday that a continued decline in sales of COVID-19 assays and ongoing difficulties securing semiconductor chips contributed to an overall 28 percent year-over-year decline in its fiscal fourth quarter revenues.

Myriad Genetics reported on Tuesday that its third quarter revenues fell 7 percent year over year primarily due to currency translations and change of estimates in diagnostic test cash collection, and non-recurring milestone payments.

In the evening of October 28, YHLO released its 2022 third quarterly report, the company achieved revenue of CNY 3.129 billion in the first three quarters of 2022, an increase of 265.06% year-on-year

Thermo Fisher Scientific said on Monday that it has reached a definitive agreement to acquire The Binding Site Group, a UK-based specialty diagnostics company, for ￡2.25 billion ($2.60 billion) in cash.

Beckman Coulter Life Sciences announced on Monday that it has inked an application development agreement with Pillar Biosciences for next-generation sequencing solutions.

Gongdong Medical Technology announced that it plans to increase the capital of its wholly owned subsidiary GD Medical with its own funds or self-raised funds of 45 million US dollars to acquire the core assets of Trademark Plastics Inc. ("TPI").

BioMérieux announced on Wednesday that its third quarter revenues rose approximately 3 percent year over year due in part to unexpectedly strong sales in its BioFire product line.

DiaSorin reported Thursday its third quarter revenues declined 5 percent year over year with waning COVID-19 testing demand, despite rising revenues across its other diagnostics businesses.